|
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conducted retrospective immunohistochemical analyses of PTC specimens, adjacent normal tissue, and benign lesions; assays of viability and gene expression in the PTC cell lines K1 and TPC-1 after genetic/pharmacological manipulation of Nrf2; and DNA sequencing at an academic medical center.
|
23766517 |
2013 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTC cell lines K1 and TPC-1 were stimulated with IL-17A and analyzed for MHC class I expression afterwards.
|
31159823 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, CD44<sup>+</sup>/CD24<sup>-</sup> cells were isolated from the TPC-1 PTC cell line and biological function assays revealed that CD44<sup>+</sup>/CD24<sup>-</sup> cells were significantly more proliferative and chemoresistant compared with CD44<sup>-</sup>/CD24<sup>-</sup> cells.
|
29201169 |
2017 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NEAT1_2 expression was markedly increased in PTC tissues and the PTC cell lines (K1 and TPC1).
|
29515109 |
2018 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Induction of epithelial to mesenchymal transition (EMT) by transforming growth factor (TGF)-beta in a PTC cell line (TPC1) led to increased MALAT1 expression, supporting a role for MALAT1 in EMT in thyroid tumors.
|
27696303 |
2017 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of RUNX2-upstream genes was evaluated by real-time PCR in Nthy-Ori 3-1 normal thyroid cells and TPC1 and BHP10-3 PTC cell lines.
|
31043660 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In our study, the proliferation of TPC-1, the papillary thyroid carcinoma cell line, was reduced by both recombinant ActA and TGF-beta1.
|
16837618 |
2006 |
|
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MiR-20b was overexpressed in the PTC cell lines K1 and TPC-1, and the effects on cell viability, migration, and invasion were evaluated.
|
27717302 |
2016 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The potential role of NCAM in tumour cell biology was investigated by silencing the NCAM gene in the TPC1 thyroid papillary carcinoma cell line.
|
17573672 |
2007 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using 76 papillary thyroid cancer(PTC) tissues and three thyroid cancer cell lines (TPC1, WRO82-1 and XTC), the expression of three genes and DNA methylation were determined by reverse transcription-PCR and methylation-specific PCR.
|
24222120 |
2013 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Matrine is a traditional Chinese medicine and has been demonstrated as a promising alternative drug for the treatment of TPC-1 human PTC.
|
30127885 |
2018 |
|
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Next, to explore the potential function of miR-96, PTC cell lines K1 and TPC1 were transiently transfected with miR-96 mimics and inhibitor.
|
26617698 |
2015 |